Benidipine
drug drugOn this page
Also known as BenidipinoBENIDIPINE HYDROCHLORIDE
Summary
Benidipine (CHEMBL2074972) is a phase-3 clinical-stage small molecule (ATC C08CA15) targeting CACNA1C; indicated across 1 condition including cardiovascular disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: C08CA15
- Targets: 1 (CACNA1C)
- Indications: 1 condition
- Clinical trials: 2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2074972 |
| Name | Benidipine |
| Type | Small molecule |
| Max phase | 3 |
| ATC | C08CA15 |
Also known as: Benidipine, Benidipino, benidipine, BENIDIPINE, BENIDIPINE HYDROCHLORIDE
Patent coverage: 1,680 distinct patent families (6,831 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,830 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CACNA1C | Cav1.2 | Antagonist | 5.31 | 0.1% | Q13936 |
Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: Alpha-2C adrenergic receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Equilibrative nucleoside transporter 1, Muscarinic acetylcholine receptor M1, D(2) dopamine receptor, Cannabinoid receptor 1, Motilin receptor, Sodium-dependent noradrenaline transporter, Alpha-1A adrenergic receptor, Histamine H1 receptor, D(3) dopamine receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D, Androgen receptor, Nuclear receptor subfamily 1 group I member 2, Voltage-dependent L-type calcium channel subunit alpha-1C.
Bioactivity
ChEMBL activities: 13 potent at pChembl ≥ 5 of 24 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P22002 | 7.85 | AC50 | 14 | nM | CHEMBL_ACT_25119894 |
| NR1I2 | 6.3 | AC50 | 500 | nM | CHEMBL_ACT_25188452 |
| OPRK1 | 5.82 | AC50 | 1500 | nM | CHEMBL_ACT_25129782 |
| CACNA1C | 5.72 | AC50 | 1900 | nM | CHEMBL_ACT_25159128 |
| KCNH2 | 5.7 | AC50 | 2010 | nM | CHEMBL_ACT_25118412 |
| ADRA1A | 5.52 | AC50 | 3000 | nM | CHEMBL_ACT_25138143 |
| ADORA3 | 5.46 | AC50 | 3500 | nM | CHEMBL_ACT_25134589 |
| MLNR | 5.46 | AC50 | 3500 | nM | CHEMBL_ACT_25189549 |
| PDE3A | 5.38 | AC50 | 4200 | nM | CHEMBL_ACT_25191083 |
| ADRA1A | 5.35 | AC50 | 4500 | nM | CHEMBL_ACT_25230115 |
| CACNA1C | 5.31 | IC50 | 4900 | nM | CHEMBL_ACT_15373202 |
| PDE4D | 5.15 | AC50 | 7100 | nM | CHEMBL_ACT_25185717 |
| SLC29A1 | 5.09 | AC50 | 8200 | nM | CHEMBL_ACT_25141892 |
Target pathways
Aggregated over 1 target gene(s): CACNA1C.
Top Reactome pathways
13 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Developmental Biology | 1 | CACNA1C |
| Metabolism | 1 | CACNA1C |
| Integration of energy metabolism | 1 | CACNA1C |
| NCAM signaling for neurite out-growth | 1 | CACNA1C |
| Muscle contraction | 1 | CACNA1C |
| Adrenaline,noradrenaline inhibits insulin secretion | 1 | CACNA1C |
| NCAM1 interactions | 1 | CACNA1C |
| Regulation of insulin secretion | 1 | CACNA1C |
| Axon guidance | 1 | CACNA1C |
| Cardiac conduction | 1 | CACNA1C |
| Phase 0 - rapid depolarisation | 1 | CACNA1C |
| Phase 2 - plateau phase | 1 | CACNA1C |
| Nervous system development | 1 | CACNA1C |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| immune system development | 1 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| heart development | 1 |
| regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | 1 |
| embryonic forelimb morphogenesis | 1 |
| camera-type eye development | 1 |
| positive regulation of adenylate cyclase activity | 1 |
| positive regulation of muscle contraction | 1 |
| calcium ion transport into cytosol | 1 |
| cardiac conduction | 1 |
| calcium ion transmembrane transport via high voltage-gated calcium channel | 1 |
| calcium ion transmembrane transport | 1 |
| cardiac muscle cell action potential involved in contraction | 1 |
| membrane depolarization during cardiac muscle cell action potential | 1 |
| membrane depolarization during AV node cell action potential | 1 |
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 3 | MONDO:0004995 | EFO:0000319 |
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02646397 | PHASE4 | UNKNOWN | Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension |
| NCT06808321 | Not specified | ENROLLING_BY_INVITATION | Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
99 molecules share ≥1 primary target. Top 99 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| CLOZAPINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C |
| PIMOZIDE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C |
| SILDENAFIL | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C |
| SOLIFENACIN | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C |
| VARDENAFIL | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C |
| ALVIMOPAN | ChEMBL | Phase 4 (approved) | CACNA1C |
| AMIODARONE | ChEMBL | Phase 4 (approved) | CACNA1C |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| AMLODIPINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | CACNA1C |
| BEPRIDIL | ChEMBL | Phase 4 (approved) | CACNA1C |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| CILOSTAZOL | ChEMBL | Phase 4 (approved) | CACNA1C |
| CISAPRIDE | ChEMBL | Phase 4 (approved) | CACNA1C |
| CLEMASTINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | CACNA1C |
| DASATINIB | ChEMBL | Phase 4 (approved) | CACNA1C |
| DIAZEPAM | ChEMBL | Phase 4 (approved) | CACNA1C |
| DIBUCAINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| DILTIAZEM | ChEMBL | Phase 4 (approved) | CACNA1C |
| DOFETILIDE | ChEMBL | Phase 4 (approved) | CACNA1C |
| DONEPEZIL | ChEMBL | Phase 4 (approved) | CACNA1C |
| DORIPENEM | ChEMBL | Phase 4 (approved) | CACNA1C |
| DROPERIDOL | ChEMBL | Phase 4 (approved) | CACNA1C |
| DULOXETINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| ESTRADIOL | ChEMBL | Phase 4 (approved) | CACNA1C |
| FLECAINIDE | ChEMBL | Phase 4 (approved) | CACNA1C |
| FLUOXETINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| FLUSPIRILENE | ChEMBL | Phase 4 (approved) | CACNA1C |
| HALOFANTRINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| HALOPERIDOL | ChEMBL | Phase 4 (approved) | CACNA1C |
| IBUTILIDE | ChEMBL | Phase 4 (approved) | CACNA1C |
| IMIPRAMINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| ISRADIPINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| KETAMINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| LACOSAMIDE | ChEMBL | Phase 4 (approved) | CACNA1C |
| LAMIVUDINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| LORATADINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| METHADONE | ChEMBL | Phase 4 (approved) | CACNA1C |
| MEXILETINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| MIBEFRADIL | ChEMBL | Phase 4 (approved) | CACNA1C |
| MITOXANTRONE | ChEMBL | Phase 4 (approved) | CACNA1C |
| NEBIVOLOL | ChEMBL | Phase 4 (approved) | CACNA1C |
| NICARDIPINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| NIFEDIPINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| NILOTINIB | ChEMBL | Phase 4 (approved) | CACNA1C |
| NIMODIPINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| NISOLDIPINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| OLICERIDINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| PAROXETINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| PHENYTOIN | ChEMBL | Phase 4 (approved) | CACNA1C |
| PINAVERIUM | ChEMBL | Phase 4 (approved) | CACNA1C |
| PITOLISANT | ChEMBL | Phase 4 (approved) | CACNA1C |
| PRENYLAMINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| PROPAFENONE | ChEMBL | Phase 4 (approved) | CACNA1C |
| PROPIVERINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| PROPRANOLOL | ChEMBL | Phase 4 (approved) | CACNA1C |
| QUINIDINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| REMIFENTANIL | ChEMBL | Phase 4 (approved) | CACNA1C |
| RISPERIDONE | ChEMBL | Phase 4 (approved) | CACNA1C |
| SAQUINAVIR | ChEMBL | Phase 4 (approved) | CACNA1C |
| SERTINDOLE | ChEMBL | Phase 4 (approved) | CACNA1C |
| SERTRALINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| SPARFLOXACIN | ChEMBL | Phase 4 (approved) | CACNA1C |
| SUNITINIB | ChEMBL | Phase 4 (approved) | CACNA1C |
| TACRINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| TERFENADINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| TERODILINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| TESTOSTERONE | ChEMBL | Phase 4 (approved) | CACNA1C |
| THIORIDAZINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| TOLTERODINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| VERAPAMIL | ChEMBL | Phase 4 (approved) | CACNA1C |
| XANOMELINE | ChEMBL | Phase 4 (approved) | CACNA1C |
| AJMALINE | ChEMBL | Phase 3 | CACNA1C |
| CETYLPYRIDINIUM | ChEMBL | Phase 3 | CACNA1C |
| CILNIDIPINE | ChEMBL | Phase 3 | CACNA1C |
| NITRENDIPINE | ChEMBL | Phase 3 | CACNA1C |
| APINOCALTAMIDE | ChEMBL | Phase 2 | CACNA1C |
| BARNIDIPINE | ChEMBL | Phase 2 | CACNA1C |
| CARVACROL | ChEMBL | Phase 2 | CACNA1C |
| CIFENLINE | ChEMBL | Phase 2 | CACNA1C |
| GALLOPAMIL | ChEMBL | Phase 2 | CACNA1C |
| SELICICLIB | ChEMBL | Phase 2 | CACNA1C |
| Z160 | ChEMBL | Phase 2 | CACNA1C |
| Apremilast | PubChem | Approved | CACNA1C |
| Baloxavir | PubChem | Approved | CACNA1C |
| Belzutifan | PubChem | Approved | CACNA1C |
| Binimetinib | PubChem | Approved | CACNA1C |
| Crizotinib | PubChem | Approved | CACNA1C |
| Desvenlafaxine | PubChem | Approved | CACNA1C |
| Enzalutamide | PubChem | Approved | CACNA1C |
| Erythromycin | PubChem | Approved | CACNA1C |
| Inavolisib | PubChem | Approved | CACNA1C |
| Moxifloxacin | PubChem | Approved | CACNA1C |
| Paliperidone | PubChem | Approved | CACNA1C |
| Rufinamide | PubChem | Approved | CACNA1C |
| Tadalafil | PubChem | Approved | CACNA1C |
| Tafamidis | PubChem | Approved | CACNA1C |
| Vorapaxar | PubChem | Approved | CACNA1C |
Related Atlas pages
- Genes: CACNA1C
- In clinical trials for: cardiovascular disorder
- Drugs: Clozapine, Pimozide, Sildenafil, Solifenacin, Vardenafil, Alvimopan, Amiodarone, Amitriptyline, Amlodipine, Astemizole, Bepridil, Chlorpromazine, Cilostazol, Cisapride, Clemastine, Clotrimazole, Dasatinib, Diazepam, Dibucaine, Diltiazem, Dofetilide, Donepezil, Doripenem, Droperidol, Duloxetine, Estradiol, Flecainide, Fluoxetine, Fluspirilene, Halofantrine, Haloperidol, Ibutilide, Imipramine, Isradipine, Ketamine, Lacosamide, Lamivudine, Loratadine, Methadone, Mexiletine, Mibefradil, Mitoxantrone, Nebivolol, Nicardipine, Nifedipine, Nilotinib, Nimodipine, Nisoldipine, Oliceridine, Paroxetine, Phenytoin, Pinaverium, Pitolisant, Prenylamine, Propafenone, Propiverine, Propranolol, Quinidine, Remifentanil, Risperidone, Saquinavir, Sertindole, Sertraline, Sparfloxacin, Sunitinib, Tacrine, Terfenadine, Terodiline, Testosterone, Thioridazine, Tolterodine, Verapamil, Xanomeline, Ajmaline, Cetylpyridinium, Cilnidipine, Nitrendipine, Apremilast, Belzutifan, Binimetinib, Crizotinib, Desvenlafaxine, Enzalutamide, Erythromycin, Inavolisib, Moxifloxacin, Paliperidone, Rufinamide, Tadalafil, Tafamidis, Vorapaxar